Piramal Pharma Share Price

Piramal Pharma Limited is a pharmaceutical company offering a portfolio of differentiated products and services through its global distribution network. Part of Piramal Group, the company has 17 global facilities with a network expanding in more than 100 countries. Piramal Group's presence in the pharma business goes back to 1988. It entered the space with the acquisition of Nicholas Laboratories in 1988. Over the years it transformed into the Piramal Healthcare network. In 2010, the pharma arm of Piramal Group sold the domestic formulations business to Abbott and diagnostic services to Super Religare Laboratories. Piramal Pharma then became part of Piramal Enterprises Limited.

Business operations

Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC) are subsidiaries of the company. PPS is the contractor development and manufacturing organisation (CDMO) under PPL, looking after end-to-end development and manufacturing solutions across the drug lifecycle.

Piramal Critical Care’s complex hospital product portfolio offers anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and other critical therapies. Its manufacturing facilities in the US and India have cleared periodic inspections by the US FDA, UK MHRA and other regulators.

The company sells its over-the-counter products like Lacto Calamine, I-Pill, Polycrol and Tetmosol through India Consumer Healthcare (ICH).

Piramal Pharma Limited was incorporated as a public firm in 2020. The company acquired the pharmaceutical business from Piramal Enterprises Limited. It received a growth equity investment from Carlyle Group Limited in the same year.

Piramal Pharma acquired a 100% stake in Convergence Chemicals Private Limited (CCPL). It also announced an expansion for antibody-drug conjugates at its Grangemouth (UK) facility and the drug substance capabilities at its Riverview facility (USA). The next year, the company acquired Hemmo Pharmaceuticals Private Limited (HPPL). The pharmaceutical business of Piramal Enterprises Limited (PEL) was demerged to PPL. The company's wholly-owned subsidiaries CCPL and HPPL were amalgamated into the firm.

Piramal Pharma has a joint venture, Allergan India Private Limited, with Allergan(now AbbVie), a key player in ophthalmology in the Indian market. It holds 49% of the paid-up capital in this venture. The company also has a minority stake of 33.33% in Yapan Bio, a company operating in the biologics/ bio-therapeutics and vaccine segments.

Piramal Pharma was listed on the Indian stock market in 2022. In FY 2023, the company launched its e-commerce website weelify.in to consolidate its presence in the e-commerce space.

Piramal Pharma’s market capitalisation stood at nearly ₹18,800 crore as of January 12, 2024. Piramal Pharma share price has moved up by 22.4% in the last one year.

Piramal Pharma Financial Highlights

• Revenue: Piramal Pharma reported revenue of ₹9,082.38 crore in FY26 vs ₹9,285.99 crore in FY25. It showed a decrease of 2.19% on a yearly basis.
• Operating Profit: Piramal Pharma reported an operating loss of ₹176.06 crore in FY26 vs ₹414.64 crore in FY25. It showed a decrease of 142.46% on a year-on-year basis.
• Net Profit: Piramal Pharma reported a net loss of ₹325.94 crore in FY26 vs ₹91.13 crore in FY25. It showed a decrease of 457.66% on a yearly basis.

Piramal Pharma Quarterly Result Highlights

• Piramal Pharma reported revenue of ₹2,652.99 crore in Sep 2026, compared with ₹2,359.33 crore in Jun 2026, representing an increase of 12.45% on a quarter-on-quarter (QoQ) basis.
• Piramal Pharma reported an operating profit of ₹81.63 crore in Sep 2026, compared with ₹7.46 crore in Jun 2026, representing an increase of 1,194.24% on a quarter-on-quarter (QoQ) basis.
• Piramal Pharma reported a profit of ₹5.03 crore in Sep 2026, compared with ₹69.39 crore in Jun 2026, reflecting an increase of 107.25% on a QoQ basis.
• The earnings per share (EPS) of Piramal Pharma stood at ₹2.46 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.